利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1763 条记录 (耗时 0.036 秒)

    INTACT MASS DETERMINATION OF PROTEIN CONJUGATED AGENT COMPOUNDS
    63.
    发明公开
    INTACT MASS DETERMINATION OF PROTEIN CONJUGATED AGENT COMPOUNDS 审中-公开
    测定完整的质量PROTEINKONJUGIERTER活性化合物

    公开(公告)号：EP2764351A1

    公开(公告)日：2014-08-13

    申请号：EP12834802.6

    申请日：2012-09-27

    申请人： Seattle Genetics, Inc.

    发明人： VALLIERE-DOUGLASS, John Fay ,  SALAS, Oscar

    IPC分类号： G01N24/00

    CPC分类号： G01N33/6848 ,  C12Q1/34

    摘要： The present invention provides methods and systems for the rapid determination of the intact mass of non-covalently associated antibody heavy chains (HC) and light chains (LC) which result from the attachment of drug conjugates to interchain cysteine residues. By analyzing the antibody-drug conjugate (ADC) using native desalting conditions, the intact-bivalent structure of the ADC, which ordinarily would decompose as a consequence of denaturing chromatographic conditions typically used for LCMS, is maintained. The mass of the desalted ADC is subsequently determined using desolvation and ionization ESI-MS conditions. The methods described herein provide for direct measurement of the intact mass of an ADC conjugated at interchain cysteine residues. The methods described herein also provide for the relative quantitation of the individual ADC species.

    ASSAY
    65.
    发明公开
    ASSAY 审中-公开

    公开(公告)号：EP2729809A1

    公开(公告)日：2014-05-14

    申请号：EP12731634.7

    申请日：2012-06-22

    申请人： DuPont Nutrition Biosciences ApS

    发明人： ISAKSEN, Mai Faurschou ,  KELLETT-SMITH, Anja Hemmingsen ,  MCLENNAN, Neil ,  GILBERT, Ceinwen ,  KYNEB, Majbritt Hauge

    IPC分类号： G01N33/558 ,  G01N33/573 ,  C12Q1/42

    CPC分类号： G01N33/573 ,  C12Q1/00 ,  C12Q1/34 ,  C12Q1/42 ,  G01N33/558 ,  G01N2333/914 ,  G01N2333/916 ,  G01N2333/924

    摘要： The present invention discloses an assay device (1) for detecting active enzyme in a sample. Said assay device (1) comprises the following components:—(a) a placement region (10) onto which the sample can be placed; (b) a matrix (20) operably connected to said placement region (10) such that the sample when present (such as placed) on said placement region (10) can migrate along said matrix (20); (c) at least one distinct capture location (30) on said matrix (20), wherein each distinct capture location (30) is distanced away from the placement region (10), and wherein the sample can migrate across said distinct capture location (30); (d) capture means (40) being present at or defining each distinct capture location (30), wherein said capture means (40) are capable of binding to said enzyme such that at least a portion of said sample of said enzyme is retained at at least one distinct capture location (30); and (e) selective indication means (50), or at least a component thereof, to provide selective indication of the presence of active enzyme bound to said capture means (40).

    摘要翻译： 本发明公开了用于检测样品中的活性酶的测定装置（1）。 所述测定装置（1）包括以下部件：（a）放置样品的放置区域（10）; （b）可操作地连接到所述放置区域（10）的矩阵（20），使得当存在（例如放置）在所述放置区域（10）上时，所述试样能够沿着所述矩阵（20）迁移; （c）在所述矩阵（20）上的至少一个不同的捕获位置（30），其中每个不同的捕获位置（30）远离所述放置区域（10），并且其中所述样品可以迁移穿过所述不同的捕获位置 30）; （d）存在于或限定每个不同捕获位置（30）的捕获装置（40），其中所述捕获装置（40）能够结合所述酶，使得所述酶的所述样品的至少一部分保留在 至少一个不同的捕获位置（30）; 和（e）选择性指示装置（50）或其至少一个组分，以提供与所述捕获装置（40）结合的活性酶的存在的选择性指示。

    TREATMENT OF PROTEINOPATHIES
    67.
    发明公开
    TREATMENT OF PROTEINOPATHIES 审中-公开
    治疗蛋白质病

    公开(公告)号：EP2723384A1

    公开(公告)日：2014-04-30

    申请号：EP12802206.8

    申请日：2012-06-22

    申请人： The General Hospital Corporation

    发明人： KRAINC, Dmitri ,  MAZZULLI, Joseph, R.

    IPC分类号： A61K47/00 ,  A61P25/28 ,  G01N33/573

    CPC分类号： C07D487/04 ,  C12Q1/34 ,  C12Q1/44 ,  G01N33/5008 ,  G01N33/573 ,  G01N2333/924 ,  G01N2500/10 ,  Y02A50/57

    摘要： The present disclosure provides technologies relating to lysosomal activation. The disclosure provides several strategies for increasing level and/or activity of lysosomal enzyme, and furthermore demonstrates the surprising applicability of such strategies in the treatment and/or prophylaxis of certain proteinopathies. Among other things, the present invention provides methods and compositions for the treatment and/or prophylaxis of proteinopathies other than lysosomal storage diseases through lysosomal activation. In particular, the present disclosure provides methods and compositions for the treatment and/or prophylaxis of neurodegenerative proteinopathies, and in particular those associated with accumulation of α-synuclein. The present disclosure specifically provides methods and compositions for the treatment and/or prophylaxis of Parkinson's disease.

    摘要翻译： 本公开提供了与溶酶体活化有关的技术。 本公开内容提供了用于提高溶酶体酶的水平和/或活性的几种策略，并且进一步证实了这些策略在治疗和/或预防某些蛋白质病中的令人惊讶的适用性。 除其他之外，本发明提供了用于通过溶酶体活化治疗和/或预防溶酶体贮积病之外的蛋白病的方法和组合物。 具体而言，本公开提供了用于治疗和/或预防神经变性蛋白病的方法和组合物，特别是与α-突触核蛋白积聚有关的方法和组合物。 本公开具体提供了用于治疗和/或预防帕金森病的方法和组合物。